Time is LIMITED to File!
ATTENTION: Dupixent Patients Diagnosed with Skin Lymphoma
ATTENTION: Dupixent Patients Diagnosed with Skin Lymphoma
Many patients who used Dupixent (dupilumab) for eczema or asthma have developed rare skin cancers, which are now under FDA review.
If you or a loved one used Dupixent for 30+ days, you may be entitled to significant compensation.
Total Injury Help has helped thousands of patients nationwide impacted by dangerous and misleading pharmaceutical products.
If you or a loved one developed Cutaneous T-Cell Lymphoma (CTCL), Sézary Syndrome, or Mycosis Fungoides after using Dupixent, you may be eligible for compensation related to:
Medical Costs: Treatment for Cutaneous T-Cell Lymphoma can exceed $120,000–$250,000 per year, including biopsies, phototherapy, systemic medications, and oncology care.
Loss of Lifestyle: Many Dupixent patients diagnosed with CTCL or related lymphomas face extended medical leave, job loss, or limited mobility due to treatment side effects and disease progression.
Emotional Damages: A cancer diagnosis brings severe emotional distress for both patients and families. You may qualify for additional compensation related to pain, anxiety, and loss of quality of life caused by Dupixent-related harm.
Get the financial support you deserve while you focus on your recovery and family.
See if you qualify today!
You Deserved to Know the Risks of Dupixent
A 2024 medical study found that patients treated with Dupixent were over 300% more likely to be diagnosed with a rare form of skin lymphoma compared to non-users.
- Dupixent (dupilumab) is a biologic injection used for eczema, asthma, and related conditions. It works by suppressing immune pathways that control inflammation (IL-4 and IL-13).
- Researchers observed an increased rate of serious conditions like Cutaneous T-Cell Lymphoma (CTCL), Sézary Syndrome, and Mycosis Fungoides among Dupixent patients.
- Experts believe Dupixent may unmask or accelerate skin lymphomas in some individuals, prompting the FDA to monitor the drug for potential safety concerns.
